Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Background Middle East respiratory syndrome coronavirus (MERS-CoV) infection is associated
with high mortality and has no approved antiviral therapy. We aimed to compare ribavirin …

… Author links open overlay panel Mustafa Saad a , Ali S. Omrani a b , Kamran Baig c , Abdelkarim
Bahloul a , Fatehi Elzein a , Mohammad Abdul Matin d , Mohei AA Selim e , Mohammed …

Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory manifestations
associated with severe coronavirus disease 2019 (COVID‐19) and thus improve clinical …

Background Ninety confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
have been reported to the World Health Organization. We report the details of a …

Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus.
Because of lack of vaccination, various studies investigated the therapeutic efficacy of …

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel enzootic
betacoronavirus that was first described in September 2012. The clinical spectrum of MERS-CoV …

Introduction A systematic literature review was undertaken to evaluate real-world use of
ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with …

… Omrani … - Ali S. Omrani made critical contributions/modifications to the study design
and execution plans, and co-wrote the initial manuscript draft. …

COVID-19 complications still present a huge burden on healthcare systems and warrant
predictive risk models to triage patients and inform early intervention. Here, we profile 893 …